𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A review of activity indices and end points for clinical trials in children with Crohn's disease

✍ Scribed by Anne M. Griffiths; Anthony R. Otley; Jeffrey Hyams; Antonio R. Quiros; Richard J. Grand; Athos Bousvaros; Brian G. Feagan; George R. Ferry

Book ID
110086331
Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
201 KB
Volume
11
Category
Article
ISSN
1078-0998

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Endpoints for clinical trials evaluating
Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease
✍ Geert R. D'Haens; Richard Fedorak; Marc LΓ©mann; Brian G. Feagan; Michael A. Kamm πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 91 KB πŸ‘ 1 views

The management of Crohn's disease is rapidly changing. The advent of potent immunomodulatory and biologic therapies has led to more demanding endpoints for clinical trials than only clinical response and remission. Complete withdrawal of corticosteroids, healing of endoscopically visible lesions, an

The need for levodopa as an end point of
The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and Ξ±-tocopherol
✍ Dr. Peter LeWitt; David Oakes; Lu Cui πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 693 KB

## Abstract Progression of Parkinson's disease (PD) can be detected through changes in clinical ratings or disability assessments. A clinical trial, Deprenyl and Alpha‐Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP), used a novel study end point: increase in parkinsonian disability to th